ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.

ValiRx plc

Mr. James Gerry Desler FCA

CFO, Company Secretary & Executive Director

Mr. Kumar  Nawani

Head of Operations

Dr. Catherine Jane Tralau-Stewart Ph.D.

Executive Director, Chief Scientific Officer & Board Officer

Mr. Mark  Treharne

Corporate Development Manager

Dr. Andrew  Carnegie

Head of Strategic Commercial Development

ValiRx plc (VAL) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

ValiRx plc (VAL) Earnings Report Date and History | LSE

VAL's next earnings is on January 3, 2025 (After Market Close)

When is the earnings report for VAL?

VAL Earnings History

VAL Stock Discussion Forum and Message Board

News for LSE: VAL